Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Deoxycholic Acid
Therapeutic Area: Nutrition and Weight Loss Product Name: Kybella
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: SWK Holdings Corporation
Deal Size: $4.3 million Upfront Cash: $4.3 million
Deal Type: Divestment August 31, 2020
Details:
Under the terms of the definitive agreement, PDL BioPharma will sale three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK Funding, LLC a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dechra Pharmaceuticals Manufacturing
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020
Details:
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
